Effect of volatile oil of amomum on expressions of platelet activating factor and mastocarcinoma-related peptide in the gastric membrane of chronic gastritis patients with helicobacter-pylori infection.
OBJECTIVE
To observe the effect of volatile oil of amomum (VOA) on the expressions of mastocarcinoma-related peptide (PS2) and platelet activating factor (PAF) in helicobacter pyloriassociated gastritis (HPG) and to analyze its potential mechanism.


METHODS
Eighty patients with HPG were randomly assigned to two groups, 42 patients in the treated group treated with 0.5 mL VOA, thrice per day; and the 38 patients in the control group receiving Western tertiary medicinal treatment. Gastroscopic picture and helicobacter pylori (HP) infection (by quick urease and Warthin-Starry stain) of the gastro-membrane, expressions of PS2 and PAF (by immunohistochemical assay and Western blotting) as well as the contents of aminohexose and phospholipid (by Neuhaus method) in the gastric membrane of all patients were detected before treatment and 4 weeks after treatment. The clinical efficacy in the two groups was compared.


RESULTS
The total effective rate in the treated group was 88.1%, which was significantly higher than that in the control group (78.9%, P<0.05). After treatment, in the treated group, gastric membranous contents of aminohexose and phospholipid was increased, expression of PS2 elevated but that of PAF lowered, all showing significant difference as compared with those in the control group (P<0.01). In the control group, the expressions of PS2 and PAF changed insignificantly. The radical eliminating rate of HP in the treated group and the control group was insignificantly different between them (76.1% vs. 65.8%, P>0.05).


CONCLUSIONS
The mechanism of VOA for anti-gastritis might be related with its action in increasing the expression of PS2 and decreasing the expression of PAF, and thus regulating the hydrophobicity of the gastric membrane.
Huang
Guo-dong
GD
Department of Integrative Medicine, the First Affiliated Hospital of Nanchang University, Nangchang, 330066, China.
Huang
Yuan-hua
YH
Xiao
Mei-zhen
MZ
Huang
Dao-fu
DF
Liu
Juan
J
Li
Jia-bang
JB
D000328:Adult; D000368:Aged; D035801:Amomum; D015153:Blotting, Western; D002908:Chronic Disease; D005260:Female; D005753:Gastric Mucosa / Q000737:chemistry*; D005756:Gastritis / Q000188:drug therapy* / Q000378:metabolism; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000378:metabolism; D016480:Helicobacter pylori; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D009822:Oils, Volatile / Q000009:adverse effects / Q000627:therapeutic use*; D010455:Peptides / Q000032:analysis*; D010743:Phospholipids / Q000032:analysis; D010972:Platelet Activating Factor / Q000032:analysis*
D009822:Oils, Volatile; D010455:Peptides; D010743:Phospholipids; D010972:Platelet Activating Factor